Compare ESP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | BDTX |
|---|---|---|
| Founded | 1928 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 171.9M |
| IPO Year | 1995 | 2020 |
| Metric | ESP | BDTX |
|---|---|---|
| Price | $62.15 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.0K | ★ 475.9K |
| Earning Date | 09-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | 28.81 | ★ 130.71 |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $46,124,325.00 | N/A |
| Revenue This Year | $13.61 | N/A |
| Revenue Next Year | $5.53 | N/A |
| P/E Ratio | $16.63 | ★ N/A |
| Revenue Growth | ★ 4.95 | N/A |
| 52 Week Low | $36.00 | $1.60 |
| 52 Week High | $74.77 | $4.94 |
| Indicator | ESP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 40.78 |
| Support Level | $60.47 | $1.76 |
| Resistance Level | $67.31 | $1.90 |
| Average True Range (ATR) | 2.53 | 0.08 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 33.73 | 26.09 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.